AstraZeneca releases clinical trials appendix outlining late-stage pipeline and upcoming data catalysts
AZN•Pipeline designations
Pipeline designations include 3 Priority Review, 5 Breakthrough or PRIME or Sakigake, 14 Fast Track, 22 Orphan, and 3 Qualified Infectious Disease products.
Late-stage pipeline and development projects
AstraZeneca highlighted 21 late-stage new molecular entities, 183 development projects, and 116 Phase II or Phase III NME or major lifecycle programs.
2026-2027 data catalysts and regulatory decisions
Key 2026-2027 catalysts include Datroway lung Phase III readouts in H2 2026, Tagrisso-Orpathys SAFFRON data in H2 2026, and PACIFIC-9 data in H2 2026.
Regulatory decisions flagged for Datroway in metastatic TNBC in the EU, Japan, and China; Imfinzi in high-risk non-muscle invasive bladder cancer in Japan; and Truqap in PTEN-deficient mHSPC in the EU.
